Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vertex Pharmaceuticals Incorporated Tibotec Pharmaceutical Limited |
---|---|
Information provided by: | Vertex Pharmaceuticals Incorporated |
ClinicalTrials.gov Identifier: | NCT00627926 |
A phase 3 study to evaluate efficacy and safety of two dosing regimens of telaprevir in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
Condition | Intervention | Phase |
---|---|---|
Hepatitis C |
Biological: Peg-Interferon-alfa-2a Drug: telaprevir Drug: placebo matching telaprevir Drug: Ribavirin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C |
Estimated Enrollment: | 1050 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Placebo matching telaprevir in combination with Pegasys® and Copegus® for 12 weeks, followed by 36 weeks of Pegasys® and Copegus®.
|
Biological: Peg-Interferon-alfa-2a
Solution for injection
Drug: placebo matching telaprevir
tablet
Drug: Ribavirin
tablet
|
2: Active Comparator
Telaprevir plus Pegasys® and Copegus® for 8 weeks, followed by 4 weeks of telaprevir matching placebo plus Pegasys® and Copegus®. Followed by 16 to 36 weeks of Pegasys® and Copegus®, depending on individual response to telaprevir.
|
Biological: Peg-Interferon-alfa-2a
Solution for injection
Drug: telaprevir
tablet
Drug: placebo matching telaprevir
tablet
Drug: Ribavirin
tablet
|
3: Active Comparator
Telaprevir plus Pegasys® and Copegus® for 12 weeks, followed by 12 to 36 weeks of Pegasys® and Copegus®, depending on individual response to telaprevir.
|
Biological: Peg-Interferon-alfa-2a
Solution for injection
Drug: telaprevir
tablet
Drug: Ribavirin
tablet
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Study Director: | Medical Monitor | Vertex Pharmaceuticals Incorporated |
Responsible Party: | Vertex Pharmaceuticals Incorporated ( Shelley George, M.D. ) |
Study ID Numbers: | VX07-950-108 |
Study First Received: | February 22, 2008 |
Last Updated: | October 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00627926 |
Health Authority: | United States: Food and Drug Administration |
Genotype 1 |
Interferon-alpha Liver Diseases Hepatitis, Chronic Ribavirin Interferons Hepatitis, Viral, Human Hepatitis |
Virus Diseases Digestive System Diseases Peginterferon alfa-2a Hepatitis C Interferon Alfa-2a Hepatitis C, Chronic |
Antimetabolites Anti-Infective Agents RNA Virus Infections Molecular Mechanisms of Pharmacological Action Flaviviridae Infections Immunologic Factors Antineoplastic Agents Growth Substances |
Physiological Effects of Drugs Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors |